JPMorgan Chase & Co. bought a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 30,657 shares of the company’s stock, valued at approximately $536,000.

Other large investors have also modified their holdings of the company. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $193,000. Ark Investment Management LLC purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $206,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $235,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Crispr Therapeutics in the second quarter worth about $273,000. Hedge funds and other institutional investors own 21.91% of the company’s stock.

In related news, major shareholder Corp /De/ Celgene sold 22,759 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $19.10, for a total value of $434,696.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the sale, the director now directly owns 8,218 shares in the company, valued at $166,085.78. The disclosure for this sale can be found here. Insiders sold 2,168,504 shares of company stock worth $42,538,573 over the last ninety days. 39.98% of the stock is currently owned by insiders.

Shares of Crispr Therapeutics AG (CRSP) opened at $27.18 on Wednesday. The firm has a market cap of $1,308.81, a P/E ratio of -20.59 and a beta of 4.64. Crispr Therapeutics AG has a one year low of $11.63 and a one year high of $30.79.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.77) earnings per share. analysts predict that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on CRSP shares. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. SunTrust Banks reissued a “hold” rating and issued a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Oppenheimer started coverage on shares of Crispr Therapeutics in a report on Thursday, December 7th. They issued a “hold” rating on the stock. Finally, Piper Jaffray Companies started coverage on shares of Crispr Therapeutics in a report on Friday, December 22nd. They issued an “overweight” rating on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.81.

TRADEMARK VIOLATION NOTICE: “30,657 Shares in Crispr Therapeutics AG (CRSP) Purchased by JPMorgan Chase & Co.” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/30657-shares-in-crispr-therapeutics-ag-crsp-purchased-by-jpmorgan-chase-co/1810355.html.

Crispr Therapeutics Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.